Cathie Wood’s ARK sells Teradyne stock, buys more Tesla

ARK disclosed a $10.84M sale of 33,812 Teradyne (TER) shares and a $11.51M purchase of 33,210 Tesla (TSLA) shares via ARKQ on April 8, 2026. The firm also sold 26,770 Roku (ROKU) shares for $2.64M and 62,882 Strata Critical Medical (SRTA) shares for $255k, while buying smaller stakes: 19,653 Kodiak AI (KDK) for $152k, 12,516 GeneDx (WGS) for $837k, 4,787 Arcturus Therapeutics (ARCT) for $40.7k, and selling 4,956 Veracyte (VCYT) for $159k. Pattern: ARK is trimming exposure to Teradyne, Roku and Strata while increasing its TSLA position and adding selective AI/biotech holdings; trades are notable for positioning but unlikely to move large-cap stocks materially.

Analysis

ARK’s activity reads as thematic reweighting rather than a pure valuation call: capital is being pulled from cyclical industrial-test and streaming-ad exposures into concentrated EV/autonomy and boutique AI/biotech microcaps. That flow can amplify volatility for mid-cap suppliers (Teradyne, Roku) for several weeks post-disclosure, creating repeatable intraday liquidity squeezes and cheap option skew to sell into.

Second-order supply-chain effects matter: sustained fund flows out of test-equipment names compress near-term OEM order visibility (procurement holds) which can delay factory upgrades for 2–6 months, trimming revenue recognition for suppliers even if end-demand later re-accelerates. Conversely, incremental weight into Tesla-like names increases implied volatility and raises financing costs for short sellers, mechanically widening bid-ask spreads across EV/autonomy suppliers.

Risks and catalysts are asymmetric across time horizons. Over days-weeks, headlines and ARK trade prints drive flow-driven price moves and option-implied volatility spikes; over 3–12 months, fundamentals (chip-test equipment backlog, FSD/autonomy monetization cadence, streaming ad cycles, biotech readouts) will dominate. Tail risks include a rapid auto-cycle slowdown or a biotech binary failure that could reverse positioning within 30–90 days, while a sustained AI capex wave would materially re-rate industrial test names over 6–18 months.

Key Decisions for Investors

• Long TSLA via a 3-month call spread (buy 1x 15–25% OTM call, sell 1x 35–45% OTM call) sized at 0.5% AUM. Rationale: capture continued thematic flow into autonomy/AI with defined premium risk; target 2–3x return if FSD/autonomy catalyst beats consensus within 90 days; stop = premium loss.
• Pair trade — long TER (15–25% pullback entry) with a 6–12 month horizon, hedge with a 25% OTM protective put. Position size 0.5% AUM. Rationale: buy the structural AI/semiconductor test exposure at a dislocated price post-flow; risk 1 unit to make 3 units if orders re-accelerate in 6–12 months; stop-loss 20% below entry without fundamental improvement.
• Short ROKU via a 2–3 month put spread (buy 1x 20% OTM put, sell 1x 35% OTM put) sized to risk 0.25% AUM. Rationale: monetize probable near-term ad revenue softness and continued fund selling; payoff 3–4x if ad weakness persists into next quarter; keep small due to potential binary upside from ad recovery.
• Tactical microcap biotech basket: allocate 0.5–1% AUM across KDK, WGS, ARCT with strict single-name caps (max 0.4% each) and 3–6 month event calendars. Rationale: ARK flow can depress prices on high-volatility names; use tight stop rules and options where available to define downside given binary trial/regulatory risk.